Skip to main content
Premium Trial:

Request an Annual Quote

NCI Seeks Studies on New 'Omics-based Cancer Technologies

NEW YORK (GenomeWeb News) – The National Cancer Institute is offering to fund researchers studying ways of using emerging cellular, molecular, and genomics technologies in cancer care.
 
These research programs will assess these technologies for how they work in regards to quality of care, cost-effectiveness, influence on cancer outcomes, progression, survival, and mortality, and in other ways, NCI said.
 
One of the programs, under an R01 funding mechanism, does not specify the amount of funding available, and the second, an R21 grant program, will give up to $275,000 over a two-year period, and up to $200,000 in a single year.
 
The tools NCI wants assessed could include those that are already in use, as well as tools that are in late stages of development or in phases of the regulatory pipeline. Collaborations between health services researchers and in clinical and translational sciences are also encouraged.
 
Clinical tools that investigators seek to study should “be directly applicable to cancer prevention, early detection, diagnosis, or treatment,” NCI stated in a funding announcement. The research should be targeted to specific DNA or RNA sequences or other specific molecules or pathways, and they should relate to genomics, proteomics, or similar fields, NCI added.
 
Technologies researchers could consider include genetic tests for cancer risk; genotyping or molecular and biochemical assays; biomarker tests for early malignancy detection; molecular profiling and tumor imaging and biomarker-based tests for cancer recurrence; pharmacogenetic or molecular assays to predict treatment outcomes; RNA interference; and toxicity and efficacy biomarker assays for monitoring treatment and drug resistance.
 
More information about the R01 and R21 programs, called “Understanding the Effects of Emerging Cellular, Molecular, and Genomic Technologies on Cancer Health Care Delivery,” may be found here and here.
 
 
 
 

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.